Clinical Trial Update: Desensitization in Kidney Allograft Using Daratumumab [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating desensitization in kidney transplantation using daratumumab has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allosensitization
• Antibody-mediated Rejection
• Kidney Transplant Rejection

Drugs mentioned

• Daratumumab (daratumumab)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Allosensitization, Kidney Transplant Rejection | Phase 1, Phase 2 | Status: COMPLETED